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SUMMARY 
Objective: To design and validate a transition readiness assessment tool for adolescents and 
young adults with epilepsy and without intellectual disability.
Methods: We adapted a general transition readiness assessment tool (TRAQ) to add epilepsy-
relevant items based on concepts in current epilepsy quality measures. The adapted tool, 
EpiTRAQ, maintained the original structure and scoring system. Concurrent with clinical 
implementation in pediatric and adult epilepsy clinics at an academic medical center, we 
assessed the validity and reliability of this adapted tool for patients 16-26 years of age. This 
process included initial validation with 302 patients who completed EpiTRAQ between October 
2017 and May 2018; repeat validation with 381 patients who completed EpiTRAQ between June 
2018 and September 2019; and retest reliability among 153 patients with more than one 
completed EpiTRAQ.
Results: Mean scores were comparable between initial and repeat validation populations 
(absolute value differences between 0.05 and 0.1); internal consistency ranged from good to 
high. For both the initial and repeat validation, mean scores and internal consistency 
demonstrated high comparability to the original TRAQ validation results. Upon retest, few 
patients rated themselves with a lower score, while the majority rated themselves with higher 
scores.
Significance: EpiTRAQ is a valid and reliable tool for assessing transition readiness in 
adolescents and young adults with epilepsy and without intellectual disability. 
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Key Point Box 
 A condition-specific transition readiness assessment tool is important to support the 
unique needs of adolescents and young adults with epilepsy.
 EpiTRAQ was adapted from a well-validated general assessment tool, with additional 
items reflecting key concepts in epilepsy quality measures.
 Concurrent with clinical implementation, we assessed the validity and reliability of 
EpiTRAQ with patients 16-26 years of age. 
 EpiTRAQ is a valid and reliable tool for assessing transition readiness in adolescents and 
young adults with epilepsy and without intellectual disability.
INTRODUCTION
Improvements in treatment and overall management of childhood epilepsy have led to more 
children and adolescents with epilepsy entering adulthood. Transition refers to the complex 
process of preparing patients and their families to move from the pediatric setting to the adult 
system of care. Although a structured program of transition has been recommended for children 
and youth with special health needs for nearly two decades,1 a recent consensus article 
underscores the paucity of evidence for successful transition of adolescents with epilepsy.2 
A key strategy to support transition involves the use of structured transition readiness 
assessments to guide the process of helping youth gain experience and confidence in their ability 
to manage their own health care.3  Repeated administration of transition readiness assessments 
over the teen years helps adolescents and young adults – as well as their providers and parents – 
to recognize the knowledge and skills they already possess, and to understand where additional 
information, explanation, or practice is warranted. 
General transition readiness assessments are useful in addressing basic elements of self-
management of health and health-related skills. However, youth with epilepsy need additional 
condition-specific knowledge and information that are not covered in general assessments.4,5 At 
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order to gain widespread use. Therefore, our objective was to design and validate a condition-
specific transition readiness assessment tool for administration to adolescents and young adults 
with epilepsy and without intellectual disability in the clinical setting.
METHODS
Tool Development. We had three key considerations in developing the epilepsy-specific tool. 
First, to minimize the burden of implementation in the clinical setting, we wanted a tool that 
could be completed in a short amount of time (e.g., in the waiting room prior to an appointment) 
with minimal staff assistance. Second, our plans included eventual adoption of the tool into our 
institution’s electronic health record (EHR), so we wanted a tool that could easily be converted 
to that format. Third, we wanted to build on the experience of our institutional colleagues in 
administering transition readiness assessments. 
In exploring these considerations, we found that colleagues had a positive experience using the 
Transition Readiness Assessment Questionnaire6 (TRAQ), a patient-reported assessment tool 
designed for youth with special healthcare needs. The TRAQ includes 20 items, organized into 
five subscales:  managing medications, appointment keeping, tracking health issues, talking with 
providers, and managing daily activities. Each TRAQ item is scored on a scale of 1-5, 
representing the lowest level to highest level of readiness, from least to most independent) based 
on the following fixed-choice responses: 1=No I don't know how; 2=No but want to learn; 3=No 
but learning; 4=Yes have started; 5=Yes always do this when I need to. 
The psychometric properties of TRAQ have been reported previously. 7,8 An evaluation of ten 
transition assessment instruments named TRAQ as the best-validated tool and the only tool with 
adequate content validity, construct validity, and internal consistency.9 
We determined that TRAQ offered the option of modification for use in epilepsy clinics, while 
maintaining the core TRAQ structure for use in other clinical settings. This dual-option structure 
would facilitate the future EHR adoption, as our epilepsy-specific tool would utilize the same 
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epilepsy-specific tool as an expansion of TRAQ, maintaining all 20 questions, the fixed-choice 
response options, and organization into five subscales. 
To determine the epilepsy-specific modifications, we reviewed the 2014 and 2017 American 
Academy of Neurology (AAN) epilepsy quality measurement set updates10,11 led by one team 
member who was involved in the development of those measures (AP). We selected fifteen 
elements that were pertinent to adolescent care and important for proper transition, and   worked 
through several revisions to craft item wording that would both reflect the AAN measure 
descriptions and fit with the response options of TRAQ. We placed each new item into one of the 
TRAQ subscales. We referred to this modified, epilepsy-specific instrument as EpiTRAQ.
Construct Validity. The AAN quality measures aim to improve the delivery of care and outcomes 
for patients with epilepsy; as such, the new EpiTRAQ questions have strong construct validity 
with regard to the care and well-being of youth with epilepsy. Table 1 presents the relationship 
between AAN quality measurement topics and the new epilepsy-specific questions. 
As an additional gauge of validity, the EpiTRAQ instrument was reviewed by two youth with 
epilepsy and a parent of an adolescent with epilepsy. All three felt that EpiTRAQ was easy to 
understand and complete; they recommended no changes. 
Implementation of EpiTRAQ Administration. EpiTRAQ was implemented in pediatric and adult 
neurology outpatient clinics at Michigan Medicine in Ann Arbor, Michigan. The Comprehensive 
Epilepsy Programs in the Departments of Neurology and Pediatrics at Michigan Medicine are 
Level 4 epilepsy programs, individually recognized by the National Association of Epilepsy 
Centers. The pediatric epilepsy program sees over 1700 children under 21 years of age for 
outpatient care each year, while the adult epilepsy program sees more than 3000 patients 
annually. 
In October 2017, as part of a quality improvement project to improve transition support, pediatric 
and adult neurology clinics began requesting EpiTRAQ completion for established patients with 
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16-26 years of age, consistent with the age range for the original TRAQ. Implementation of 
EpiTRAQ and assessment of its reliability and validity were determined to be non-regulated 
quality improvement activity by the University of Michigan Medical School Institutional Review 
Board.
To support initial implementation, a member of the study team identified eligible patients each 
week by reviewing the log of upcoming appointments to assess age and diagnostic eligibility. A 
notation of “transition survey” was added to the EHR information about the scheduled 
appointment, to alert clinic staff that this was an EpiTRAQ-eligible patient. The EHR also 
flagged eligibility for repeat EpiTRAQ completion at least 6 months after the prior date of 
completion. 
Clinic check-in staff provided a paper copy of the EpiTRAQ to identified patients and asked 
them to complete the form. When parents indicated their child was not cognitively capable of 
completing the form, parents were encouraged to complete the form, checking a box on the form 
to indicate parent-reported data. EpiTRAQ forms were completed in the waiting area prior to the 
appointment or while waiting in the exam room. EpiTRAQ forms were collected at clinic check-
out.
Approach to Validity and Reliability Assessment. In conjunction with the clinical implementation 
of EpiTRAQ, we evaluated the reliability and validity of the modified tool. Drawing on 
published guidance12, we did not conduct a comprehensive factor analysis and validation of the 
revised instrument analysis of all items), including core TRAQ questions. First, we determined a 
priori that we would maintain all items in the established, validated TRAQ instrument, and use a 
similar process for completion and scoring.. . Second, the additional epilepsy-specific questions 
are clinically relevant and meaningful for this population as they were based on existing AAN 
epilepsy quality measures. 
 
Therefore, our overall approach to EpiTRAQ validity and reliability assessment was to assess the 
internal consistency of the overall EpiTRAQ instrument and each subscale using Cronbach’s 
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deviation for each subscale and for the overall instrument. We also compared EpiTRAQ to 
TRAQ, comparing mean scores for questions common to both instruments. 
Initial Validation. Our initial validation used EpiTRAQ data collected from 302 patients seen in 
pediatric and adult epilepsy clinics between October 2017 and May 2018. Consistent with the 
original TRAQ validation, we included only patient-completed forms. We used the established 
TRAQ scoring protocol to generate the mean score and standard deviation for each subscale and 
for the overall instrument. For the subscale Managing Daily Activities, we calculated the mean 
for the subset of 9 questions targeted to all patients using data for the total population and re-
calculated the mean for the full subscale (including the 2 questions targeted to females) using 
data for female patients only. For the overall scale, we calculated the mean score for the subset 
of 33 questions targeted to all patients using data for the total population and re-calculated the 
mean for all 35 questions (including the 2 questions targeted to females) using data for female 
patients only.
We assessed the internal consistency of each EpiTRAQ subscale and the overall tool using 
Cronbach’s alpha.13 For the overall scale and the subscale Managing Daily Activities, we 
calculated the Cronbach’s alpha for the subset of questions targeted to all patients using data for 
the total population, and re-calculated the Cronbach’s alpha for the full subscale (including the 2 
questions targeted to females) using data for female patients only. 
We also conducted a parallel analysis of the 20 core TRAQ questions, comparing mean scores 
and internal consistency (Cronbach’s alpha) for the overall scale and each subscale to the 
original published TRAQ validation.8  
Repeat Validation. We conducted a second validation test for 381 patients who completed at 
least one EpiTRAQ between June 2018 and February 2019. For patients who completed more 
than one EpiTRAQ during that timeframe, we included data from the more recent form in the 
repeat validation. We calculated mean scores and assessment of internal consistency for the 
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above. We repeated the comparisons for the 20 core TRAQ questions to the original published 
TRAQ validation.
Retest Reliability. To assess the reliability of EpiTRAQ over time, we analyzed results patterns 
for 153 patients who completed two or more EpiTRAQ forms between October 2017 and May 
2019. For patients with more than two forms, we compared the initial and the most recent form, 
determining for each question if the self-reported score at Time 2 was lower, higher or the same 
as the score at Time 1.  We calculated the total number of lower and higher scores for each 
patient, and performed bivariate analyses using the Chi-square test to explore the association 
between the total number of lower and higher scores and the average time between patient age 
and the initial and repeat EpiTRAQ completion.
RESULTS
Table 2 presents the characteristics of the 3 validation populations.  
Validation of EpiTRAQ. Table 3 presents the mean scale and subscale EpiTRAQ scores for the 
initial and repeat validation populations. Mean scores are slightly higher for repeat validation 
than initial validation but otherwise very comparable. The absolute value of differences 
comparing initial and repeat validations range from 0.05 to 0.1. 
Table 3 also presents the assessment of EpiTRAQ’s internal consistency for the initial and repeat 
validation populations. The range of Cronbach alpha values for both initial and repeat validation 
is (0.78, 0.95) and (0.77, 0.94) respectively. These capture ranges of good to high reliability 
within subscales and for the overall score. 
Comparison of EpiTRAQ to TRAQ. Table 4 presents the comparison of mean scale and subscale 
scores for only the 20 questions included in the core TRAQ. Mean scores for initial and repeat 
validation show very small differences when compared with the mean score for the original 
TRAQ. The absolute value of differences in mean scores (TRAQ – EpiTRAQ) between the 
corresponding subscales and overall score of the original TRAQ and initial and repeat validation 
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Table 5 presents the internal consistency for the 20 questions included in the core TRAQ, 
comparing the initial and repeat validation populations to the original TRAQ validation.8 The 
internal consistency is nearly identical across the three groups for the overall scale, and for 
subscales on appointment keeping and talking with providers. Internal consistency is similar 
across groups for the other subscales (differences of no more than 0.11).
Retest Reliability. For the 153 unique patients included in the retest reliability analysis, the time 
between completion of the initial and repeat form ranged from 5 to 17 months, with 10.5% at 1-5 
months, 41.8% at 6-11 months, and 47.7% at 12-17 months.
Table 6 presents the proportion of patients who gave themselves a lower, higher or same score at 
Time 2 compared to Time 1, for each EpiTRAQ. Overall, 30.1% had 0-1 questions with a lower 
score at Time 2; 35.3% had 2-4 questions with a lower score at Time 2; 24.2% had 5-9 questions 
with a lower score at Time 2; and 10.5% had ≥10 questions with a lower score at Time 2. There 
were no significant associations between the number of questions with a lower Time 2 score and 
either age or time between completion of the initial and repeat form.
The majority of patients rated themselves with higher scores: 17% had 0-2 questions with a 
higher score at Time 2; 40.5% had 3-9 questions with a higher score at Time 2; and 41.8% had 
≥10 questions with a higher score at Time 2. Younger age was associated with reporting higher 
scores at Time 2: 56.8% of patients 16-18 years reported ≥10 questions with a higher score at 
Time 2, compared to 44.4% of patients 19-21 and 29.7% of patients ≥22 years (p=0.005). There 
was no significant association between the number of questions with a higher Time 2 score and 
time between completion of the initial and repeat form.
DISCUSSION
Transition from pediatric to adult care should be based on readiness, not simply age-eligibility 
criteria. For patients with epilepsy, lack of or poor transition may be associated with suboptimal 
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isolation.4,14 Thus, an epilepsy-specific transition readiness assessment tools is important to 
support the unique transition needs of this population, including condition-specific knowledge 
and information that are not covered in general assessments.4,5
Many transition readiness assessment tools are geared toward the primary care setting. However, 
primary care pediatricians may feel unprepared to discuss disease-specific issues related to 
young adulthood, such as reproductive health issues.15 In contrast, physicians and other clinical 
staff in the specialty neurology clinic are well prepared to discuss epilepsy-specific information 
and management strategies for youth preparing for the adult system of care. An epilepsy-specific 
transition readiness assessment tool appropriate for implementation in the neurology clinic 
setting may serve to facilitate such discussions. 
In working toward an epilepsy-specific tool, we chose to make incremental changes to a widely 
used instrument to improve its relevance for a target population. Thus, EpiTRAQ is grounded 
within the well-validated TRAQ instrument. TRAQ has been used in other condition-specific 
populations and has been translated into multiple languages.6 TRAQ’s broad use is evidence of 
its value to providers, patients, and parents. Another strength of EpiTRAQ is its close 
relationship to AAN quality measures of recommended health care delivery and important 
outcomes for youth with epilepsy.10,11 Quality measures are developed from evidence-based 
published information where a gap in implementation of this evidence exists.  The close 
correspondence of EpiTRAQ to the AAN quality measures reinforces the validity of the tool and 
may represent a rationale for adoption in neurology clinics.  
We prioritized ease of clinical implementation in developing and testing EpiTRAQ. Although 
the process of identifying patients eligible for EpiTRAQ was done manually at the outset of 
implementation, we quickly moved toward use of the EHR for this purpose. Similarly, initial 
completion of EpiTRAQ was done on paper copies; we plan to add the option for EpiTRAQ 
completion in electronic form via our patient portal, with direct entry into the patient’s EHR. 
Finally, our experience may represent an option for other clinics that want to incorporate 
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Results of our EpiTRAQ validation demonstrated that mean scores compared favorably to the 
original TRAQ validation8, for both the initial and repeat validation populations. Among the 
three subscales with new epilepsy-specific questions, mean scores for Managing Medications 
were higher, Tracking Health Issues were slightly lower, and Managing Daily Activities 
equivalent to the mean scores from the original TRAQ validation. Mean scores for the two 
subscales without new questions (Appointment Keeping, Talking with Providers) were higher 
than those in the original TRAQ validation. Internal consistency for EpiTRAQ was also 
comparable to the original TRAQ, with all but one subscale achieving a Cronbach’s alpha of 
high (≥0.90) or very good (0.8-0.89), with the remaining subscale as good (0.70-0.79).13 
Moreover, internal consistency for two of the three subscales with new epilepsy-specific 
questions (Tracking Health Issues, Managing Daily Activities) was higher for EpiTRAQ than for 
the original TRAQ validation; in contrast, internal consistency for Managing Medications was 
lower for EpiTRAQ than the original TRAQ validation. Internal consistency for the two 
subscales without new questions (Appointment Keeping, Talking with Providers) was nearly 
identical to the original TRAQ validation.8
Finally, retest reliability of EpiTRAQ was strong. Over 80% of adolescent and young adult 
patients gave themselves higher ratings on at least 3 items at Time 2, which occurred at least 6 
months later than Time 1, and younger age was associated with an increase in scores from Time 
1 to Time 2s. In this population of patients 16-26 years of age, we might expect more 
opportunities to increase knowledge and confidence in younger patients, who may be newly 
encountering the self-management and knowledge concepts reflected in the EpiTRAQ items. 
This would be consistent with the original TRAQ validation, which showed higher scores among 
older patients.8 Still, over one third of adolescent and young adult patients gave themselves lower 
ratings on at least 5 items at Time 2. It is unknown whether this reflects a true decrease in 
patients’ knowledge or self-management skills, or perhaps an emerging awareness that they are 
not confident about certain topics. 
There are several limitations of EpiTRAQ. First, the established response structure for TRAQ 
does not include an option for “not applicable”; this may have been useful for patients who are 
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TRAQ, we did not include parent-reported responses in this validation exercise. However, a 
considerable proportion of youth with epilepsy have cognitive deficits; as such, further work to 
understand the value of EpiTRAQ for parents of this subset of epilepsy patients is warranted. 
Third, we targeted EpiTRAQ to ages 16-26; while this is consistent with TRAQ, it should be 
noted that EpiTRAQ was not designed to assess transition readiness among younger adolescents 
who are just beginning the transition process. Finally, there is a lack of research demonstrating a 
link between transition readiness assessment results and clinical outcomes, both for EpiTRAQ 
and the original TRAQ; this may be, in part, due to the lack of metrics that determine transition 
success.4 There is a need for additional research to understand the link between EpiTRAQ and 
patient outcomes. 
Overall, EpiTRAQ may be a valid and reliable tool for assessing transition readiness in 
adolescents and young adults with epilepsy without major cognitive deficit or intellectual 
disability. Additional work is needed to explore the association with longitudinal changes in 
EpiTRAQ scores and clinical outcomes over time.
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Table 1. Correspondence of EpiTRAQ Questions with American Academy of Neurology Quality 
Measurement Topics  
 
AAN Quality Measure New EpiTRAQ question (Subscale Placement) 
Seizure frequency for 
patients with epilepsy* 
Do you know how to keep track of your seizures? 
Subscale: Tracking Health Issues 
Counseling for women of 
childbearing potential with 
epilepsy* 
Can you describe how seizures can affect your ability to have children? 
[asked only for female patients] 
Subscale: Tracking Health Issues 
If you become pregnant, can you explain how seizures affect your 
pregnancy? [asked only for female patients] 
Subscale: Managing Daily Activities 
Can you explain how seizure medications and birth control medications 
affect one another? 
Subscale: Managing Daily Activities 
Seizure intervention 
specified at each 
encounter# 
 
Can you name your seizure medications? 
Subscale: Managing Medications 
Do you know what to do if you know that you are going to have a seizure? 
Subscale: Tracking Health Issues 
Do you know how to use rescue medications to stop a long or back-to-back 
seizure? 
Subscale: Managing Medications 
Do you know how a seizure action plan is used? 
Subscale: Tracking Health Issues 
Etiology, seizure type, and 
epilepsy syndrome 
specified at each 
encounter# 
Can you explain what type of seizures you have? 
Subscale: Tracking Health Issues 
Can you explain why you have epilepsy? 
Subscale: Tracking Health Issues 
Querying and intervention 
for side effects of anti-
seizure therapy specified 
at each encounter# 
 
Can you describe how epilepsy and seizure medications affect bone health? 
Subscale: Managing Daily Activities 
Can you describe how other medications and alcohol affect your seizure 
medications? 
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Personalized epilepsy 
safety issue and education 
provided yearly# 
 
Can you explain how epilepsy affects school or having a job? 
Subscale: Managing Daily Activities 
Can you explain activities that you are not allowed to do? 
Subscale: Managing Daily Activities 
Can you describe how long you have to be seizure free before you are 
allowed to drive a car? 
Subscale: Managing Daily Activities 
 #from AAN 2014 quality measurement topics 
 *from AAN 2017 quality measurement topics 
 
 
Table 2. Characteristics of the Validation Populations 



















































Table 3. Scoring and Internal Consistency in Validation Populations 
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Managing medications (6) 3.88 (0.97) 0.78 3.97 (0.92) 0.77 
Appointment keeping (7) 3.58 (1.31) 0.92 3.68 (1.27) 0.92 
Tracking health issues (9) 3.50 (1.01) 0.82 3.56 (1.00) 0.82 
Talking with providers (2) 4.63 (0.75) 0.80 4.68 (0.72) 0.81 
Managing daily activities          
All (9) 3.82 (0.89) 0.85 3.88 (0.91) 0.85 
Females (11) 3.73 (0.87) 0.87 3.79 (0.90) 0.88 
Overall         
All (33) 3.74 (0.87) 0.95 3.81 (0.84) 0.94 




Table 4. Comparison of Mean Scores for Core TRAQ Questions 







Managing medications (4) 4.04 (1.05) 4.15 (0.99) 3.93 (1.07) 
Appointment keeping (7) 3.58 (1.31) 3.68 (1.27) 3.57 (1.10) 
Tracking health issues (4) 3.46 (1.17) 3.52 (1.15) 3.53 (1.10) 
Talking with providers (2) 4.63 (0.75) 4.68 (0.72) 4.54 (0.93) 
Managing daily activities (3) 4.31 (0.91) 4.35 (0.92) 4.33 (0.96) 




Table 5. Comparison of Internal Consistency (Cronbach’s alpha) for Core TRAQ Questions 







Managing medications (4) 0.76 0.75 0.86 
Appointment keeping (7) 0.92 0.92 0.90 
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Talking with providers (2) 0.80 0.81 0.80 
Managing daily activities (3) 0.75 0.78 0.67 











Can you name your seizure medications? 8.8 77.7 13.5 
Do you take medications correctly and on your own? 6.8 81.8 11.5 
Do you know what to do if you are having a bad reaction to your medications? 19.5 51.7 28.9 
Do you fill a prescription if you need to? 11.3 61.3 27.3 
Do you reorder medications before they run out? 14.1 54.9 31.0 
Do you know how to use rescue medications to stop a long or back-to-back 
seizure? 
15.9 52.2 31.9 
Do you call the doctor’s office to make an appointment? 17.7 53.1 29.3 
Do you follow-up on any referral for tests, check-ups or labs? 14.7 52.0 33.3 
Do you arrange for your ride to medical appointments? 9.5 70.8 19.7 
Do you call the doctor about unusual changes in your health (For example: An 
increase in seizure activity or allergic reactions)? 
14.3 55.8 29.9 
Do you apply for health insurance if you lose your current coverage? 17.2 48.5 34.3 
Do you know what your health insurance covers? 18.9 44.1 37.1 
Do you manage your money & budget household expenses (For example: use 
checking/debit card)? 
15.7 49.0 35.4 
Can you explain what type of seizures you have? 16.2 62.8 21.0 
Can you explain why you have epilepsy? 18.3 51.1 30.7 
Do you know what to do if you know that you are going to have a seizure? 15.3 54.9 29.9 
Do you know how to keep track of your seizures? 11.7 60.0 28.3 
Do you know how a seizure action plan is used? 16.3 45.4 38.3 
Do you fill out the medical history form, including a list of your allergies? 10.8 62.2 27.0 
Do you keep a calendar or list of medical and other appointments? 16.3 52.4 31.3 
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Do you get financial help with school or work? 23.3 50.0 26.7 
Do you tell the doctor or nurse what you are feeling? 8.3 73.8 17.9 
Do you answer questions that are asked by the doctor, nurse, or clinic staff? 4.8 83.5 11.7 
Do you help plan or prepare meals/food? 13.9 62.8 23.4 
Do you keep home/room clean or clean-up after meals? 14.3 62.9 22.9 
Do you use neighborhood stores and services? (For example: Grocery stores and 
pharmacy stores?) 
9.9 73.9 16.2 
Can you explain how epilepsy affects school or having a job? 8.6 69.3 22.1 
Can you explain activities that you are not allowed to do? 14.2 68.1 17.7 
Can you describe how long you have to be seizure free before you are allowed 
to drive a car? 
8.5 79.6 12.0 
Can you describe how other medications and alcohol affect your seizure 
medications? 
17.3 58.3 24.5 
Can you describe how seizures can affect your ability to have children? 14.5 46.4 39.1 
Can you describe how epilepsy and seizure medications affect bone health? 13.5 46.1 40.4 
If you become pregnant, can you explain how seizures affect your pregnancy? 
(Female only) 
12.8 47.4 39.7 
Can you explain how seizure medications and birth control medications affect 
one another? (Female only) 
20.5 42.3 37.2 
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